We are live on ! Find out more
XLO icon

Xilio Therapeutics
XLO

24 hedge funds and large institutions have $22M invested in Xilio Therapeutics in 2026 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

39.89% more ownership

Funds ownership: 5.41% → 45.3% (+40%)

13% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 8

13% less capital invested

Capital invested by funds: $25.4M → $22M (-$3.4M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

35% less funds holding

Funds holding: 37 → 24 (-13)

63% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 19

Holders
24
Holders Change
-13
Holders Change %
-35.14%
% of All Funds
0.3%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.02%
New
7
Increased
7
Reduced
8
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$1.13M
2
CP
Caligan Partners
New York
+$918K
3
SCM
Stonepine Capital Management
Oregon
+$452K
4
Renaissance Technologies
Renaissance Technologies
New York
+$204K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$112K

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.56M
2
SC
Stempoint Capital
New York
-$1.3M
3
EAM
Empery Asset Management
New York
-$757K
4
GCM
Ghisallo Capital Management
Massachusetts
-$538K
5
Citadel Advisors
Citadel Advisors
Florida
-$279K
Name Holding Trade Value Shares
Change 		Change in
Stake
SC
26
Stempoint Capital
New York
– -$1.3M -145,002 Closed
EAM
27
Empery Asset Management
New York
– -$757K -84,503 Closed
Citadel Advisors
28
Citadel Advisors
Florida
– -$279K -31,158 Closed
Northern Trust
29
Northern Trust
Illinois
– -$42.6K -4,758 Closed
Two Sigma Investments
30
Two Sigma Investments
New York
– -$39.7K -4,431 Closed
BCM
31
Bridgeway Capital Management
Texas
– -$35.9K -4,006 Closed
Jane Street
32
Jane Street
New York
– -$26.9K -3,006 Closed
HF
33
HRT Financial
New York
– -$20K -2,278 Closed
Mariner
34
Mariner
Kansas
– -$16K -1,786 Closed
LPL Financial
35
LPL Financial
California
– -$13.4K -1,500 Closed
Raymond James Financial
36
Raymond James Financial
Florida
– -$12K -1,340 Closed
XT
37
XTX Topco
Cayman Islands
– -$11.1K -1,236 Closed
DF
38
Dunhill Financial
United Kingdom
– -$6.58K -734 Closed
IAMOG
39
Investors Asset Management of Georgia
Georgia
– -$6.4K -714 Closed
PFG
40
Pinnacle Financial Group
Illinois
– -$6.4K -714 Closed
BlackRock
41
BlackRock
New York
– -$1.3K -146 Closed
PWMG
42
Private Wealth Management Group
New Jersey
– -$199 -22 Closed
Bank of America
43
Bank of America
North Carolina
– -$167 -19 Closed
1
2

XLO Hedge Fund Activity: Q1 2026 in Review

24 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q1 2026, worth a combined $22M — down 13% from $25.4M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of XLO and 7 opened new positions — a net loss of 12 holders — while 8 trimmed existing stakes and 7 added.

The largest buyer was Bain Capital Life Sciences Investors, adding an estimated $1.13M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $2.56M sold.

  • 24 institutional investors held Xilio Therapeutics (XLO) as of Q1 2026, down from 37 in Q4 2025.
  • Funds reported $22M of Xilio Therapeutics stock for Q1 2026, down 13% quarter-over-quarter.
  • 7 funds opened new Xilio Therapeutics positions in Q1 2026 and 19 closed out, a net change of -12 holders.
  • The largest Xilio Therapeutics buyer in Q1 2026 was Bain Capital Life Sciences Investors, an estimated $1.13M added.
  • The largest Xilio Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $2.56M sold.

Based on aggregated 13F filings for Q1 2026.